1.
ClinicalTrials.gov; 07/02/2024; TrialID: NCT06251011
Clinical Trial Register
| ICTRP | ID: ictrp-NCT06251011
ABSTRACT
Condition:
COVID-19;Long COVID-19;Cardiopulmonary Function;Physical FunctionIntervention:
Behavioral: Exercise trainingPrimary outcome:
Cardiopulmonary function;Patient's quality of life;Functional capacity;Anxiety and depression;Insomnia;Cognitive function;Muscle strengthCriteria:
Inclusion Criteria:
- Age between 20-60 years old
- Positive in COVID-19 testing
- Good communication and understanding
- Independent mobility
Exclusion Criteria:
- Cannot complete the study protocol
2.
TCTR; 01/09/2022; TrialID: TCTR20220901002
Clinical Trial Register
| ICTRP | ID: ictrp-TCTR20220901002
ABSTRACT
Condition:
The monoclonal antibody neutralizes the potency of AZD7442 can protect cancer patients to Coronarvirus 2019 infectionCoronavirus disease , Monoclonal Neutralizing Antibody AZD7442 (Tixagevimab- Cilgavimab),covid-19 vaccine ;Coronavirus disease , Monoclonal Neutralizing Antibody AZD7442 (Tixagevimab- Cilgavimab),covid-19 vaccine
Intervention:
Injection Monoclonal antibody,NSS injection;Experimental Drug,Placebo Comparator Drug;Monoclonal antibody,PlaceboPrimary outcome:
Symptomatic COVID infection 180 days percentCriteria:
Inclusion criteria: 1. Low-risk patients or high-risk groups aged 18 years and over.2. Weight greater than or equal to 40 kg.
3. Patients with Hematologic malignancy, breast cancer, lung cancer and colon cancer. who are receiving cancer treatment or have been treated for cancer within 6 months from the date of study (by assessing survival for more than 6 months).
People who have received at least 3 doses of Covid-19 vaccine and received the latest dose of vaccine for more than 2 weeks and not more than 3 months.
5. Understand Thai language and be able to communicate with the researcher to assess side effects from treatment. Able to use communication technology equipment
6. Can be monitored
7. Consent and sign to participate in the research
Exclusion criteria: 1. Pregnant or lactating women
2. Infected with Coronavirus 2019 within 3 months before participating in the research.
3. Has hepatic disease (child C) or end-stage renal disease (ESRD not on hemodialysis or not on hemodialysis at least twice a week).
4. Metastatic or terminal cancer (by assessing survival time less than 3 months)
5. Patients who are bedridden and unable to be treated are outpatients.
6. Previously received other neutralizing monoclonal antibody drugs within 60 days.
7. People who have had an allergic reaction to Tixagevimab/Cilgavimab.
8. People who have received the latest dose of Covid-19 vaccine for more than 3 months.
3.
Immunogenicity and safety after vaccinated with BBIBP-CorV (COVID-19 vaccine) in Thai pregnant women
TCTR; 23/09/2021; TrialID: TCTR20210923013
Clinical Trial Register
| ICTRP | ID: ictrp-TCTR20210923013
ABSTRACT
Condition:
Pregnant womenCOVID-19
SARS-CoV-2 vaccine
Vaccine
Pregnant
BBIBP-CorV
Sinopharm;COVID-19
SARS-CoV-2 vaccine
Vaccine
Pregnant
BBIBP-CorV
Sinopharm
Intervention:
Vaccinated Thai pregnant women with BBIBP-CorV at 1 course (2 dose at interval 28 days);Experimental Biological/Vaccine;BBIBP-CorV vaccinationPrimary outcome:
Immunogenicity after BBIBP-CorV vaccination 1 month after completed vaccination Immunoglobulin and neutralizing antibody to SARS-CoV-2Criteria:
Inclusion criteria: - Thai pregnant women, vaccinated with BBIBP-CorV at Chulabhorn Hospital- Age at least 18 years old
- Gestational age at 1st vaccinated at least 12 complete weeks, confirmed by ultrasonographic measurement
- Willing to keep contact for information after vaccinated
- No history of fever or illness within 14 days before vaccinated
- Not been diagnosed of SARS-CoV-2 infected
- Not been vaccinated with any other type SARS-CoV-2 vaccine
Exclusion criteria: - Deny to complete 2-doses of BBIBP-CorV vaccine
- Multiple gestation
- Immunocompromised or receiving immunosupressive agents
- Anaphylaxis allergic reaction to BBIBP-CorV vaccine
- Diagnosed with any congenital infections such as Rubella, Toxoplasmosis, Parvovirus B-19, Zika virus or Syphilis
- Fetal structural or chromosome abnormalities, or abnormal prenatal aneuploidy screening has not yet been confirmed